A new look at drugs targeting malignant melanoma-An application for mass spectrometry imaging

Proteomics

Volumn 14, Issue 17-18, 2014, Pages 1963-1970

  Sugihara, Yutaka ^a   Végvári, Ákos ^b,c   Welinder, Charlotte ^a   Jönsson, Göran ^a   Ingvar, Christian ^c   Lundgren, Lotta ^a   Olsson, Håkan ^a   Breslin, Thomas ^a   Wieslander, Elisabet ^a   Laurell, Thomas ^b   Rezeli, Melinda ^b   Jansson, Bo ^d   Nishimura, Toshihide ^c   Fehniger, Thomas E ^b,c   Baldetorp, Bo ^a   Marko Varga, György ^b,c,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d BioInvent International AB   (Sweden)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomedicine; Clinical studies; Malignant melanoma; Mass spectrometry imaging; Personalized medicine; Protein sequencing

Indexed keywords

3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO) N (2 HYDROXYETHOXY) 5 [(3 OXO 1,2 OXAZINAN 2 YL)METHYL]BENZAMIDE; AXITINIB; B RAF KINASE; DABRAFENIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PIMASERTIB; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; DISEASE COURSE; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; GENE OVEREXPRESSION; HOSPITAL; HUMAN; IN VITRO STUDY; LYMPH NODE METASTASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MULTICENTER STUDY (TOPIC); NONHUMAN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR LOCALIZATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DELIVERY SYSTEM; MASS SPECTROMETRY; METABOLISM; MOLECULAR IMAGING; PROCEDURES;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; INDOLES; MELANOMA; MOLECULAR IMAGING; PROTO-ONCOGENE PROTEINS B-RAF; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SULFONAMIDES;

EID: 84908608666     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300476     Document Type: Article

References (55)

1. Tsao, H., Atkins, M. B., Sober, A. J., Management of cutaneous melanoma. N. Engl. J. Med. 2004, 351, 998-1012.
2. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F. et al., Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009, 27, 6199-6206.
3. Blanke, C. D., Demetri, G. D., vonMehren, M., Heinrich, M. C. et al., Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 2008, 26, 620-625.
4. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B. et al., Improved survival with vemurafenib in melanomawith BRAF V600E mutation. N. Engl. J.Med. 2011, 364, 2507-2516.
5. Bollag, G., Hirth, P., Tsai, J., Zhang, J. et al., Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467, 596-599.
6. Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R. et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366, 707-714.
7. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T. et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lanc 2012, 380, 358-365.
8. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P. et al., Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367, 107-114.
9. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R. et al., Combined BRAF and MEKinhibition in melanomawith BRAF V600 mutations. N. Engl. J. Med. 2012, 367, 1694-1703.
10. Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S. et al., MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a nonrandomised, open-label phase 2 study. LancOncol. 2013, 14, 249-256.
11. Leijen, S., Middleton, M. R., Tresca, P., Kraeber-Bodere, F. et al., Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin. Cancer Res. 2012, 18, 4794-4805.
12. Adjei, A. A., Cohen, R. B., Franklin,W., Morris, C. et al., Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 2008, 26, 2139-2146.
13. Patel, S. P., Lazar, A. J., Papadopoulos, N. E., Liu, P. et al., Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 2013, 119, 799- 805.
14. Fury, M. G., Sherman, E., Haque, S., Korte, S. et al., A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2012, 69, 591-598.
15. Hainsworth, J. D., Infante, J. R., Spigel, D. R., Peyton, J. D. et al., Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010, 116, 4122-4129.
16. MacKenzie, M. J., Ernst, S., Johnson, C., Winquist, E., A phase I study of teMALDI-MSIrolimus and metformin in advanced solid tumours. Invest. New Drugs 2012, 30, 647-652.
17. Fruehauf, J., Lutzky, J., McDermott, D., Brown, C. K. et al., Multicenter, phase II study of axitinib, a selective secondgeneration inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin. Cancer Res. 2011, 17, 7462-7469.
18. Plummer, R., Madi, A., Jeffels, M., Richly, H. et al., A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71, 93-101.
19. Caprioli, R. M., Farmer, T. B., Gile, J., Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 1997, 69, 4751-4760.
20. Stoeckli, M., Farmer, T. B., Caprioli, R. M., Automated mass spectrometry imaging with a matrix-assisted laser desorption ionization time-of-flight instrument. J. Am. Soc. Mass Spectrom. 1999, 10, 67-71.
21. Caprioli, R. M., Farmer, T. B., Zhang, H. Y., Stoeckli, M.,Molecular imaging of biological samples by MALDIMS. Abstr. Pap. Am. Chem. Soc. 1997, 214, 113.
22. Wiseman, J. M., Ifa, D. R., Zhu, Y., Kissinger, C. B. et al., Desorption electrospray ionization mass spectrometry: imaging drugs and metabolites in tissues. Proc. Natl. Acad. Sci. U S A 2008, 105, 18120-18125.
23. Goodwin, R. J., Iverson, S. L., Andren, P. E., The significance of ambient-temperature on pharmaceutical and endogenous compound abundance and distribution in tissues sections when analyzed by matrix-assisted laser desorption/ ionizationmass spectrometry imaging. Rapid Commun. Mass Spectrom. 2012, 26, 494-498.
24. Nilsson, A., Forngren, B., Bjurstrom, S., Goodwin, R. J. et al., In situ mass spectrometry imaging and ex vivo characterization of renal crystalline deposits induced in multiple preclinical drug toxicology studies. PloS ONE 2012, 7, e47353.
25. Harris, F. T., Rahman, J. S., Hassanein, M., Qian, J. et al., Acyl-coenzyme a binding protein regulates beta oxidation required for growth and survival of non-small cell lung cancer. Cancer Prev. Res. 2014, 7, 748-757.
26. Chaurand, P., Rahman, M. A., Hunt, T., Mobley, J. A. et al., Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol. Cell. Proteomic. 2008, 7, 411-423.
27. Willems, S. M., van Remoortere, A., van Zeijl, R., Deelder, A. M. et al., Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J. Pathol. 2010, 222, 400-409.
28. Agar, N. Y., Malcolm, J. G., Mohan, V., Yang, H. W. et al., Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal. Chem. 2010, 82, 2621-2625.
29. Elsner, M., Rauser, S., Maier, S., Schone, C. et al., MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognosticmarkers in Barrett's adenocarcinoma. J. Proteomic. 2012, 75, 4693-4704.
30. Hassanein, M., Rahman, J. S., Chaurand, P., Massion, P. P., Advances in proteomic strategies toward the early detection of lung cancer. Proc. Am. Thorac. Soc. 2011, 8, 183-188.
31. Aichler, M., Elsner, M., Ludyga, N., Feuchtinger, A. et al., Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J. Pathol. 2013, 230, 410-419.
32. Balluff, B., Rauser, S., Meding, S., Elsner, M. et al., MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am. J. Pathol. 2011, 179, 2720-2729.
33. Fehniger, T. E., Vegvari, A., Rezeli, M., Prikk, K. et al., Direct demonstration of tissue uptake of an inhaled drug: proof-ofprinciple study using matrix-assisted laser desorption ionization mass spectrometry imaging. Anal. Chem. 2011, 83, 8329-8336.
34. Marko-Varga, G., Vegvari, A., Rezeli, M., Prikk, K. et al., Understanding drug uptake and binding within targeted disease micro-environments in patients: a new tool for translational medicine. Clin. Transl. Med. 2012, 1, 1-8.
35. Hardesty,W.M., Caprioli, R. M., In situmolecular imaging of proteins in tissues using mass spectrometry. Anal. Bioanal. Chem. 2008, 391, 899-903.
36. Lazova, R., Seeley, E. H., Keenan,M., Gueorguieva, R., Caprioli, R. M., Imaging mass spectrometry-a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am. J. Dermatopathol. 2012, 34, 82-90.
37. Prideaux, B., Stoeckli, M., Mass spectrometry imaging for drug distribution studies. J. Proteomic. 2012, 75, 4999-5013.
38. Lietz, C. B., Gemperline, E., Li, L.,Qualitative and quantitative mass spectrometry imaging of drugs and metabolites. Adv. Drug Deliv. Rev. 2013, 65, 1074-1085.
39. Marko-Varga, G., Fehniger, T. E., Rezeli, M., Dome, B. et al., Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J. Proteomic. 2011, 74, 982-992.
40. Nilsson, A., Fehniger, T. E., Gustavsson, L., Andersson, M. et al., Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PloS ONE 2010, 5, e11411.
41. Chan, T. L., Zhao, W., Leung, S. Y., Yuen, S. T., BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003, 63, 4878-4881.
42. Yuen, S. T., Davies, H., Chan, T. L., Ho, J. W. et al., Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62, 6451-6455.
43. Cohen, Y., Xing, M.,Mambo, E., Guo, Z. et al., BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95, 625-627.
44. Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A. et al., High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTCRAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63, 1454-1457.
45. Schindler, G., Capper, D., Meyer, J., Janzarik, W. et al., Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011, 121, 397-405.
46. Singer, G., Oldt, R., 3rd, Cohen, Y., Wang, B. G. et al., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95, 484-486.
47. Badalian-Very, G., Vergilio, J. A., Degar, B. A., Mac-Conaill, L. E. et al., Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010, 116, 1919- 1923.
48. Ku, X., Heinzlmeir, S., Liu, X., Medard, G., Kuster, B., A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors. J. Proteomics 2014, 96, 44-55.
49. Chamrad, I., Rix, U., Stukalov, A., Gridling, M. et al., Aminiaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J. Proteome Res. 2013, 12, 4005-4017.
50. Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S. et al., Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Translat. Med. 2010, 8, 67.
51. Spittle, C., Ward, M. R., Nathanson, K. L., Gimotty, P. A. et al., Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J. Mol. Diagn. 2007, 9, 464-471.
52. Hay, R., MacRae, E., Barber, D., Khalil, M. et al., BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch. Pathol. Lab. Med. 2007, 131, 1361-1367.
53. Willmore-Payne, C., Holden, J. A., Tripp, S., Layfield, L. J., Human malignant melanoma: detection of BRAF- and c-kitactivating mutations by high-resolution amplicon melting analysis. Hum. Pathol. 2005, 36, 486-493.
54. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E. et al., PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigm. Cell Melanoma R. 2010, 23, 190-200.
55. Ugurel, S., Thirumaran, R. K., Bloethner, S., Gast, A. et al., BRAF and N-RASmutations are preserved during short time in vitro propagation and differentially impact prognosis. PloS One 2007, 2, e236.